AptarGroup, Inc.
ATRHealthcareNASDAQMedical Instruments & Supplies · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, AptarGroup, Inc. focuses on Medical Instruments & Supplies services and products. AptarGroup, Inc. designs and manufactures drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, fragrance, facial skincare, color cosmetics, personal. The company carries a $8.05B market cap, placing it firmly in the mid-cap category. The company operates through three segments: Pharma, Beauty, and Closures.
Market Cap
$8.05B
Beta
0.34
P/E (TTM)
22.40
P/E (Fwd)
20.49
EPS (TTM)
$5.65
EPS (Fwd)
$6.18
ROE
13.5%
ROA
6.1%
Cash
$197.3M
Total Debt
$1.41B
Free CF
$266.0M
52W Change
-1.8%
Annual Financials
Cash vs Debt
Where ATR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ATR finished 0.06% below its 150-day moving average ($124.70) and 1.19% below its 200-day moving average ($126.13). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ATR overbought or oversold?
At the October 20, 2026 close, ATR's RSI(14) was 54.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $197.3M in cash, though total debt stands at $1.41B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $266.0M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 13.5%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $3.32B to $3.78B.
ATR's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. No single metric tells the full story. Reviewing ATR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.